Supernus Pharma (SUPN) Misses Q1 EPS by 2c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.29, $0.02 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $153.76 million versus the consensus estimate of $137.74 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance